Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSurgical Innovations Regulatory News (SUN)

Share Price Information for Surgical Innovations (SUN)

Share Price is delayed by 15 minutes
Get Live Data
0.475    0.00 (0.00%)
Bid:
0.45
Ask:
0.50
Spread: 0.05 (11.111%)
Market Cap: £4.43m
SUN Live PriceLast checked at - London Stock Exchange

Intraday Surgical Innovations Share Chart

Trading update

10 Apr 2025 07:00

RNS Number : 4081E
Surgical Innovations Group PLC
10 April 2025
 

Surgical Innovations Group plc

("Surgical Innovations", the "Company", or the "Group")

 

Trading Update

 

Further to the announcement made on 12th February 2025, Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative medical technology for minimally invasive surgery ("MIS"), provides an update on expectations for the Company's full year results for the year ended 31 December 2024 ("FY24 Results").

 

The Company now expects to report revenues of not less than £11.8m and adjusted EBITDA¹ of between £0.0m to £0.4m.

 

Further to the announcement made on 1st April 2025, the Company confirms that it remains on track to publish its FY24 Results in May 2025.

 

Notes

¹Adjusted EBITDA is earnings before interest, tax, depreciation and amortization adjusted by deducting non-recurring exceptional costs, impairment of intangible acquisition costs and share based payment costs.

 

For further information please contact:

 

Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Tel: 0113 230 7597

Brent Greetham, CFO

 

 

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Alex Bond / Oliver Platts

 

 

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or si@walbrookpr.com

Paul McManus / Lianne Applegarth 

Mob: 07980 541 893 / 07584 391 303

 

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.

 

We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs, the Company's Reposable portfolio enables healthcare providers to reduce both plastic waste and their CO2 footprint as they strive for net zero.

 

 

Further information

Further details of the Group's businesses and products are available on the following websites:

 

www.sigroupplc.com

www.surginno.com

www.elementalhealthcare.co.uk

 

To receive regular updates by email, please contact si@walbrookpr.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBIGDSLSGDGUC
Date   Source Headline
27th Jun 20223:15 pmRNSResult of AGM
27th Jun 20227:00 amRNSAGM Trading Statement
25th May 20227:00 amRNSPosting of 2021 Annual Report & Accounts
9th May 202212:41 pmRNSDirector/PDMR Shareholding
23rd Mar 20227:00 amRNSFinal Results
21st Mar 20227:00 amRNSProduct launch in partnership with CMR Surgical
10th Mar 20227:00 amRNSNotice of Annual Results
17th Jan 20227:00 amRNSYear-end Trading Update
15th Nov 20217:00 amRNSChanges to Board Structure & CFO Appointment
10th Nov 20215:43 pmRNSGrant of Options
15th Sep 20217:00 amRNSHalf-year Report
27th Aug 20217:00 amRNSNotice of Interim Results
9th Jul 20212:29 pmRNSDirector/PDMR Shareholding
22nd Jun 20215:26 pmRNSResult of AGM
22nd Jun 20217:00 amRNSAGM Trading Statement
21st Jun 20217:00 amRNSWithdrawal of AGM Resolution
21st May 20217:00 amRNSPosting of Annual Report& Accounts & Notice of AGM
25th Mar 20217:00 amRNSFinal Results
22nd Mar 20217:00 amRNS3-year Exclusive UK distribution agreement
8th Mar 20217:00 amRNSNotice of annual results
15th Feb 20217:00 amRNS5-year USA distribution agreement
9th Feb 20217:00 amRNSLaunch of the Green Surgery Challenge
8th Jan 20217:00 amRNSDistalmotion’s Dexter Robot receives CE Mark
7th Jan 20217:00 amRNSFuture board change
21st Dec 20207:00 amRNSTrading update
17th Dec 20207:00 amRNSUS distribution agreement signed with Adler
7th Dec 20203:00 pmRNSReplacement of Auditor
2nd Dec 20207:00 amRNSProduct launch for Cellis Breast
25th Nov 20207:00 amRNSCentre for Sustainable Healthcare collaboration
25th Sep 202011:50 amRNSHolding(s) in Company
23rd Sep 20205:20 pmRNSHolding(s) in Company
21st Sep 20201:46 pmRNSHolding(s) in Company
18th Sep 20204:08 pmRNSResult of AGM
17th Sep 202012:54 pmRNSResult of Fundraise
17th Sep 20207:01 amRNSProposed Fundraise
8th Sep 20207:00 amRNSHalf-year Report
21st Aug 20207:00 amRNSNotice of results and Change of AGM 2020 Date
10th Aug 20205:57 pmRNSHolding(s) in Company
10th Jun 20207:00 amRNSPostponement of the Annual General Meeting 2020
4th Jun 20204:50 pmRNSDirector/PDMR Shareholding
4th Jun 20207:00 amRNSNHS Sustainability Webinar
28th May 20207:00 amRNSUpdate on trading &extension to banking facilities
31st Mar 20207:00 amRNSFinal Results
27th Mar 20203:05 pmRNSNotice of results and trading update
13th Jan 20207:00 amRNSYear-end Trading Update
11th Nov 20196:09 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSDirector/PDMR Shareholding
5th Nov 20192:56 pmRNSDirector/PDMR Shareholding
25th Oct 20193:12 pmRNSDirector/PDMR Shareholding
7th Oct 20194:12 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.